Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase II/III Study Of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab In Patients With Unresectable State III Or Stage IV Melanoma
Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator?s Choice in HLAA02:01-positive Participants with Previously Treated Advanced Melanoma TEBE-AM
Study Type: Treatment
Phase: II/III
NCTID: NCT05549297
Principal Investigator:
Gary Doolittle
A Phase II Study of Brentuximab Vedotin in Combination with Checkpoint Inhibitor CPI Therapy in Subjects with Metastatic Solid Tumors After Progression on Prior PD-1 Inhibitor Treatment
A Phase III, Randomized, Double-blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
A Randomized Phase II Study of ATR Inhibition in Advanced PD-L1-refractory Merkel Cell Carcinoma: The MATRiX Trial
Study Type: Treatment
Phase: II
NCTID: NCT05947500
Principal Investigator:
Nina Mathew
A Randomized, Controlled, Multicenter, Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician?s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Study Type: Treatment
Phase: III
NCTID: NCT06264180
Principal Investigator:
Gary Doolittle
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon alpha-2b for Resected High-Risk Melanoma.
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma Phase I and II and Other Solid Tumors Phase I Only.
A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneious Melanoma
Study Type: Treatment
Phase: III
NCTID: NCT03860883
Principal Investigator:
Luke Selby